1. Scrip
  2. >>Business

Shionogi's Xocova Extends Global Reach Through First MPP Sublicenses

 
• By Lisa Takagi

The first sublicensing deals through MPP for Shionogi's oral COVID antiviral Xocova with seven firms in China, India, Ukraine and Vietnam suggest the global debut of generic versions will come earlier than usual after the original, which continues in multiple global Phase III programs in various settings. While sales hopes are high, the drug may also be hit by a price cut in its first and biggest market so far – Japan.  

Xocova's sublicensing deal suggests its global debut may come earlier than the original product.
Xocova's sublicensing deal to provide drug in 117 low- and-middle-income countries. • Source: Shutterstock

The first sublicensing agreements for Shionogi & Co. Ltd.’s Xocova (ensitrelvir; S-217622) have been reached following the Japanese firm's alliance with the Medicines Patent Pool (MPP) last year. Deals have now been signed for the oral COVID-19 antiviral with seven generic firms in China, India, Ukraine and Vietnam.

If they successfully proceed, the arrangement means that officially licensed generic versions can be launched earlier than usual after the original product outside Japan, the only market where the protease 3CL inhibitor has been approved and launched so far

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.